News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Immunotherapy’ clear

  • Dana-Farber researchers report in the New England Journal of Medicine that treating advanced melanoma patients initially with the combination of the immunotherapy drugs nivolumab and ipilimumab achieves a much higher response rate than treatment with ipilimumab alone.

Tags: Melanoma, Immunotherapy

  • Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

Tags: EGFR, Genomics, LungCancer, OvarianCancer, ProstateCancer, Lymphoma, Immunotherapy

  • A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.

Tags: MultipleMyeloma, Leukemia, Immunotherapy

  • Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Tags: Lymphoma, Immunotherapy

  • Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.

Tags: Melanoma, Immunotherapy

  • Researchers reported survival of patients with advanced melanoma was improved when they received an immune stimulant along with a checkpoint blocker immunotherapy drug. The combination also resulted in fewer serious side effects compared with patients who got only the immunotherapy drug, ipilimumab.

Tags: Melanoma, Immunotherapy

  • Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.

Tags: BasicResearch, LungCancer, Immunotherapy

  • F. Stephen Hodi, MD, and colleagues report the immunotherapy drug nivolumab continues to show long-term effectiveness in treating metastatic melanoma, achieving a three-year survival rate of 41 percent against the deadly skin cancer.

Tags: Melanoma, Immunotherapy

  • Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

Tags: LungCancer, Immunotherapy

  • Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.

Tags: Melanoma, Immunotherapy

Showing 1-10 of 12 items